Top 10 Biotech Stocks To Watch For 2019

Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication.

Welcome to another edition of “3 Things In Biotech You Should Learn Today,” a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research.

And before we get started, if you haven’t already, be sure to check out this Progenics article that has drawn some interesting conversation from stakeholders!

Pfizer heads for gold with biosimilar rituximab

Company: Pfizer (PFE)

Therapy: Biosimilar rituximab

Disease: Indolent non-Hodgkin lymphoma

News: PFE announced that its randomized, double-blind clinical trial comparing PF-05280586 to Roche’s (OTCQX:RHHBY) rituximab has reached its primary endpoint, which was equivalence in terms of overall response rate in first-line treatment of low burden follicular lymphoma. This will likely be one of the last hurdles to be cleared before PFE moves forward with a marketing application.

Top 10 Biotech Stocks To Watch For 2019: Amgen Inc.(AMGN)

Advisors’ Opinion:

  • [By Todd Campbell]

    Neulasta has been one of Amgen’s (NASDAQ:AMGN) crown jewels for years, but following FDA approval of Mylan’s (NASDAQ:MYL) Neulasta biosimilar this week, Amgen could see Neulasta’s revenue slow to a trickle. Is Mylan about to deliver a big blow to Amgen’s market share? Read on to find out what’s at stake for these companies and their investors.

  • [By Shane Hupp]

    Investors sold shares of Amgen, Inc. (NASDAQ:AMGN) on strength during trading hours on Thursday. $63.15 million flowed into the stock on the tick-up and $134.51 million flowed out of the stock on the tick-down, for a money net flow of $71.36 million out of the stock. Of all stocks tracked, Amgen had the 0th highest net out-flow for the day. Amgen traded up $2.11 for the day and closed at $185.79

  • [By Cory Renauer]

    Patient Amgen Inc.(NASDAQ:AMGN) shareholders have seen the stock quadruple in price over the past decade, plus they’ve enjoyed one of the fastest-growing dividends in biopharma. Now that the company’s launched a new migraine headache drug, investors are wondering if the former highflier can put on another memorable performance.

Top 10 Biotech Stocks To Watch For 2019: ArQule Inc.(ARQL)

Advisors’ Opinion:

  • [By Joseph Griffin]

    ValuEngine upgraded shares of ArQule (NASDAQ:ARQL) from a buy rating to a strong-buy rating in a research report released on Tuesday.

    Several other equities analysts have also issued reports on ARQL. Zacks Investment Research upgraded ArQule from a hold rating to a buy rating and set a $2.50 price objective for the company in a research report on Tuesday, March 20th. BidaskClub upgraded ArQule from a buy rating to a strong-buy rating in a research report on Saturday, March 24th. B. Riley set a $4.00 price objective on ArQule and gave the company a buy rating in a research report on Monday, March 26th. Leerink Swann upgraded ArQule from a market perform rating to an outperform rating in a research report on Thursday, April 5th. Finally, Roth Capital boosted their price objective on ArQule from $5.00 to $6.00 and gave the company a buy rating in a research report on Tuesday, April 17th. One equities research analyst has rated the stock with a sell rating, five have assigned a buy rating and two have issued a strong buy rating to the stock. The company has a consensus rating of Buy and a consensus target price of $5.35.

  • [By Joseph Griffin]

    Shares of ArQule, Inc. (NASDAQ:ARQL) were down 5.4% during trading on Wednesday . The company traded as low as $4.71 and last traded at $4.73. Approximately 3,358,864 shares traded hands during trading, an increase of 289% from the average daily volume of 863,008 shares. The stock had previously closed at $5.00.

  • [By Logan Wallace]

    ValuEngine downgraded shares of ArQule (NASDAQ:ARQL) from a strong-buy rating to a buy rating in a research report sent to investors on Saturday.

    Several other brokerages also recently issued reports on ARQL. Zacks Investment Research upgraded shares of ArQule from a hold rating to a buy rating and set a $2.75 target price for the company in a research note on Tuesday, May 8th. B. Riley set a $4.00 target price on shares of ArQule and gave the company a buy rating in a research note on Monday, March 26th. Roth Capital raised their target price on shares of ArQule from $5.00 to $6.00 and gave the company a buy rating in a research note on Tuesday, April 17th. BidaskClub upgraded shares of ArQule from a hold rating to a buy rating in a research note on Saturday, May 19th. Finally, Leerink Swann upgraded shares of ArQule from a market perform rating to an outperform rating in a research note on Thursday, April 5th. One research analyst has rated the stock with a sell rating, six have issued a buy rating and one has issued a strong buy rating to the company. The company has an average rating of Buy and a consensus price target of $5.35.

Top 10 Biotech Stocks To Watch For 2019: Alnylam Pharmaceuticals Inc.(ALNY)

Advisors’ Opinion:

  • [By Brian Orelli]

    The delay in an FDA decision for Tegsedi puts it behind competitor Alnylam Pharmaceuticals (NASDAQ:ALNY), which expects to hear from the FDA by Aug. 11 for its hATTR drug patisiran. But Sarah Boyce, the president at Akcea Therapeutics, doesn’t think a few months will really matter: “We don’t really feel that’s going to have any impact and the drugs will be close enough together from a launch perspective. So not really [going] to make any adjustments, and we’re very well prepared to be ready to launch following approval.”

  • [By Brian Orelli]

    Alnylam Pharmaceuticals (NASDAQ:ALNY) released first-quarter results last week, but all eyes were looking forward as the company waits for a potential approval of its hereditary TTR amyloidosis (ATTR) drug, patisiran.

  • [By Joseph Griffin]

    BidaskClub lowered shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) from a strong-buy rating to a buy rating in a research report released on Monday.

  • [By Shane Hupp]

    Get a free copy of the Zacks research report on Alnylam Pharmaceuticals (ALNY)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Sean Williams, Chuck Saletta, and Brian Feroldi]

    So, which biotech stocks should you consider buying in June? That’s a question we posed to three of our healthcare-focused investors. Interestingly enough, mid-cap biotech stocks are the clear flavor of the month. If biotech is on your radar in June, our investors suggest you consider Ionis Pharmaceuticals (NASDAQ:IONS), Spark Therapeutics (NASDAQ:ONCE), and Alnylam Pharmaceuticals (NASDAQ:ALNY).

Top 10 Biotech Stocks To Watch For 2019: Biogen Idec Inc(BIIB)

Advisors’ Opinion:

  • [By ]

    This week we get our first look at quarterly numbers from major drug and biotech giants such as AbbVie (ABBV)  , Amgen (AMGN)  , Biogen (BIIB) , Biomarin Pharmaceuticals (BMRN)  and Action Alerts PLUS holding Eli Lilly (LLY) , which all provide the market a glimpse of how the first quarter was for the industry over the next few days,” according to Real Money Pro columnist Bret Jensen.

  • [By Stephan Byrd]

    Ladenburg Thalmann Financial Services Inc. cut its stake in shares of Biogen Inc (NASDAQ:BIIB) by 16.9% in the first quarter, HoldingsChannel.com reports. The fund owned 8,962 shares of the biotechnology company’s stock after selling 1,817 shares during the period. Ladenburg Thalmann Financial Services Inc.’s holdings in Biogen were worth $2,453,000 at the end of the most recent reporting period.

  • [By Keith Speights]

    This has been a bad year for Biogen (NASDAQ:BIIB) so far — the biotech’s stock has dropped more than 10% since it began. But 2018 has been horrible for Acadia Pharmaceuticals (NASDAQ:ACAD), which has seen its share price plunge nearly 40%.

  • [By Brian Orelli]

    Drug-developer Biogen (NASDAQ:BIIB) reported a pretty strong earningsincrease in the first quarter. While revenue growth wasn’t as solid, investors appear to be giving management a pass, thanks to its explanations on why slowing first-quarter sales aren’t a sign of future trouble.

Leave a Reply

Your email address will not be published. Required fields are marked *